1-4 of 4
Douglas J. DeMarini, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Ryan C. Lynch, MD, Shankara Paneesha, MD, Abraham Avigdor, MD, Matthew S McKinney, Björn E Wahlin, MD PhD, John S Hrom, David Belada, MD PhD, Miguel Canales, David Cunningham, MD FRCP, FMedSci, Liliana Devizzi, Nicholas Morley, Fred Zheng, MD, Douglas J DeMarini, PhD, Wei Jiang, PhD, Marek Trněný, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-134869
Published: 2020
Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

Pier Luigi Zinzani, MD, Vincent Delwail, Shankara Paneesha, MD, Simon Rule, MD PhD, Alejandro Martin Garcia-Sancho, MD PhD, Ana Marin-Niebla, MD PhD, Gilles Salles, MD PhD, Juan-Manuel Sancho, MD PhD, Vibeke Vergote, MD, Vittorio Ruggero Zilioli, MD, Fred Zheng, MD, Douglas J DeMarini, PhD, Wei Jiang, PhD, Amitkumar Mehta, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-134609
Published: 2020
Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)

Amitkumar Mehta, MD, Marek Trněný, MD, Jan Walewski, MD, Vincent Ribrag, MD, Caroline Dartigeas, MD, Jacob Haaber Christensen, MD PhD, Fabrizio Pane, MD, Guillermo Rodríguez, MD, Michal Taszner, MD, Parameswaran Venugopal, MD, Vittorio Ruggero Zilioli, MD, Fred Zheng, MD, Douglas J DeMarini, PhD, Wei Jiang, PhD, Pier Luigi Zinzani, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-134872
Published: 2020
Journal Articles

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Andres Forero-Torres, MD, Rod Ramchandren, MD, Abdulraheem Yacoub, MD, Michael S. Wertheim, MD, William J. Edenfield, MD, Paolo Caimi, MD, Martin Gutierrez, MD, Luke Akard, MD, Carolina Escobar, MD, Justin Call, MD, Daniel Persky, MD, Swami P. Iyer, MD, Douglas J. DeMarini, PhD, Li Zhou, PhD, Swamy Yeleswaram, PhD, Tycel J. Phillips, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 410.
https://doi.org/10.1182/blood.V130.Suppl_1.410.410
Published: 2017